LEADER 05829nam 2200565Ia 450 001 9910829127303321 005 20200520144314.0 010 $a1-62081-098-0 035 $a(CKB)2560000000103724 035 $a(EBL)3022467 035 $a(SSID)ssj0000915997 035 $a(PQKBManifestationID)11490804 035 $a(PQKBTitleCode)TC0000915997 035 $a(PQKBWorkID)10875558 035 $a(PQKB)11731154 035 $a(MiAaPQ)EBC3022467 035 $a(Au-PeEL)EBL3022467 035 $a(CaPaEBR)ebr10719465 035 $a(OCoLC)847526872 035 $a(EXLCZ)992560000000103724 100 $a20120125d2012 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aLupus $esymptoms, treatment and potential complications /$fThiago Devesa Marquez and Davi Urgeiro Neto, editors 205 $a1st ed. 210 $aHappauge, NY $cNova Science Publishers$dc2012 215 $a1 online resource (221 p.) 300 $aDescription based upon print version of record. 311 $a1-62081-078-6 320 $aIncludes bibliographical references and index. 327 $aIntro -- LUPUS: SYMPTOMS, TREATMENT AND POTENTIAL COMPLICATIONS -- LUPUS: SYMPTOMS, TREATMENT AND POTENTIAL COMPLICATIONS -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I: Lupus Erythematosus: A Comprehensive Review -- Abstract -- Abbreviations -- Defining Lupus -- Lupus Incidence and Prevalence -- Causes of Lupus -- Diagnosing Lupus -- Autoantibodies in Lupus -- Lupus Blood Tests -- Urine Testing -- Other Tests -- Pregnancy and Contraception for Women with Lupus -- Current Research in Lupus -- Genetics in Lupus -- Biomarkers -- The Disease Process -- Lupus and the Skin, Hair and Mucosae -- Lupus and the Sun -- Lupus and the Musculoskeletal System -- Podiatric Care in Lupus -- Lupus and the Mucosae -- Mixed Connective Tissue Disease, or Overlap Syndrome -- Differential Diagnoses of Lupus -- Coping with Lupus among Family and Friends -- Treatment -- NSAIDs -- Antimalarials -- Corticosteroids -- Immunosuppressives -- BLyS-Specific Inhibitors -- Other Lupus Therapies -- Alternative and Complementary Therapies -- References -- Chapter II: Autoantibody-Producing B Cellsand B Cell Therapy in Systemic Lupus Erythematosus - Possible New Targets of Novel Subsets of RP105-NegativeB Cells -- Abstract -- Introduction -- Section 1. B Cell Biology in SLE -- Section 2. Therapies of Targeting B Cells in SLE -- Conclusion -- Reference -- Chapter III: Neuropsychiatric Manifestations in Systemic Lupus Erythematosus -- Abstract -- Introduction -- Classification Criteria -- NPSLE Epidemiology -- Clinical Relevance -- Risk Factors for NPSLE -- Pathophysiology -- Diagnosis -- Clinical and Laboratory Investigation -- Therapeutic Strategies in NPSLE -- Conclusion -- Acknowledgments -- References -- Chapter IV: Treatment in Systemic Lupus Erythematosus -- Abstract -- Introduction -- Conventional Therapies -- B-Cell Targeting. 327 $aT-Cell Targeting and Co-Stimulatory Blockade -- Anticytokines Therapy -- Complement Inhibition -- Conclusion -- Acknowledgments -- References -- Chapter V: Hematologic Manifestations of Systemic Lupus Erythematosus -- Anemia -- Leukopenia -- Lymphopenia -- Neutropenia -- Thrombocytopenia -- Bone Marrow as a Target Organ in SLE -- Hematological Manifestations, SLE Subsets and Prognosis -- References -- Chapter VI: Interleukin-21 in Systemic Lupus Erythematosus: Pathogenic Relevance and Therapeutic Applications -- Abstract -- Introduction: Overview on Systemic Lupus Erythematosus -- Multiple Roles for B Cells in SLE -- IL-21 Is aCritical Regulator of B Cell Responses -- IL-21 and SLE -- Treatment of Spontaneous Lupus Mice Using Agents Able to Block IL-21/IL-21R Signaling -- Conclusion -- References -- Chapter VII: Metabolic Syndrome and Inflammatory Cytokines in Systemic Lupus Erythematosus -- Abstract -- Introduction -- CVD in SLE -- Traditional Risk Factors -- Non-Traditional Risk Factors -- CVD Features and Cytokines Involved on SLE -- Relationship between SLE Treatment in Patients with MetS -- What Is the Best Treatment to MetS in SLE Patients? -- Conclusion and Perspective Future -- Acknowledgments -- References -- Chapter VIII: Pulmonary Hypertensionin Systemic Lupus Erythematosus -- Definition -- Classification -- Pulmonary Manifestations in SLE -- Epidemiology -- Pathogenesis -- Clinical Manifestations -- Diagnostic Methods -- Autoantibodies -- Pregnancy -- Treatment -- Immunosuppressive Therapy -- Sildenafil -- Prostanoids -- Endothelin Receptor Antagonists -- Transplantation -- Prognosis -- Conclusion -- References -- Chapter IX: Dual Roles for Antibodies in Lupus Nephritis -- Abstract -- The Origins of Pathogenic Antibodies in Autoimmunity -- Pathogenic Antibodies in Lupus -- Anti-DsDNA IgM Protects against Lupus Nephritis -- Conclusion. 327 $aReferences -- Chapter X: Treatment of Systemic Lupus Erythematosus with Intravenous Immunoglobulins: Case Studies -- Abstract -- Introduction -- Case Study 1 -- Case Study 2 -- Discussion -- Conclusion -- References -- Chapter XI: APRV (Airway Pressure-Release Ventilation) as Supportive Management for Diffuse Alveolar Hemorrhage with Systemic Lupus Erythematosus -- Abstract -- Introduction -- APRV and DAH -- Cases -- References -- Index. 606 $aSystemic lupus erythematosus 606 $aAutoimmune diseases 615 0$aSystemic lupus erythematosus. 615 0$aAutoimmune diseases. 676 $a616.7/72 701 $aMarquez$b Thiago Devesa$01709830 701 $aNeto$b Davi Urgeiro$01709831 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910829127303321 996 $aLupus$94099938 997 $aUNINA